Merck has reported its second-quarter results, which were better than expected. The company's sales were higher than anticipated, driven by the performance of its cancer treatment Keytruda. The strong sales of Keytruda have also led Merck to raise its revenue forecast for the full year.

This update was announced on Tuesday, according to reports. Further details on Merck's second-quarter results and updated forecast can be found through Reuters, the source of this information. Local readers in Galveston may want to consult the original report for more information on the company's performance.